Search Results
Results found for "GPCR Therapeutics"
- Dr. Juan José Fung | Dr. GPCR Ecosystem
Juan José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting GPCR heteromers in cancer, headquartered in Seoul, Korea, with an R&D facility in the SF Brian Kobilka , studying the dimerization of GPCRs. Dr. Juan José Fung on the web LinkedIn GPCR Therapeutics Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review.
- Dr. Josephine (Pina) Cardarelli | Dr. GPCR Ecosystem
Pina Cardarelli, CSO for GPCR Therapeutics Inc., based in South Korea, has recently been named President of GPCR Therapeutics, USA, a newly incorporated Biotechnology company in the Bay Area. The company’s mission is to discover and develop highly effective cancer therapeutics by targeting heteromers She was an integral contributor to two therapeutics that are FDA approved, Yervoy and Opdivo. patents including anti-PD-1 patents, 22 EP patents, and greater than 100 global patents centered around therapeutic
- University | Dr. GPCR Ecosystem
together to advance biology and therapeutics. 📚 Learn faster. 🤝 Connect deeper. 🔬 Drive discoveries Explore 200+ expert talks that bring GPCR discoveries to life From structural biology to therapeutics agonists and antagonists shape efficacy, signaling, and therapeutic potential. orthosteric drugs and uncover the power of allosteric modulators and kinetic insights to unlock new therapeutic Take the Next Step You're building the future of GPCR therapeutics.
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
technology for high-throughput screening of pharmacological compound libraries to identify potential therapeutic "Ana Lilia Moreno Salinas (2), Arturo Mancini (1), Raida Jallouli (2), Richard Leduc (2) (1)Domain Therapeutics Laurent Sabbagh on the web Domain Therapeutics Characterizing hADGRE5/CD97 Activation and Signaling: Domain Therapeutics North America Inc., Montreal, Quebec, Canada 3. ), with a particular focus on the adhesion GPCRs (aGPCRs) family.
- Session VIII | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program ADGRG1/GPR56 regulates survival of terminally differentiated CD8+ T cells Cheng-Chih Hsiao Adhesion GPCR Attendees About Douglas Tilley "Research in the Tilley laboratory focuses primarily upon aspects of GPCR in the regulation of physiologic/pathologic function in the heart in an effort to uncover novel therapeutic directions for HF, including adhesion GPCRs (AGPCRs).
- How sensitive can a GPCR really be | Dr. GPCR Ecosystem
Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights Home → Flash News → How sensitive can a GPCR really be How sensitive can a GPCR really be? translational impact — giving us new ways to think about receptor pharmacology, biased agonism, and therapeutic precision. 🔗 Listen here → https://www.ecosystem.drgpcr.com/dr-gpcr-podcast/leadership-luck-and-gpcr-signaling GPCR Premium → https://www.ecosystem.drgpcr.com/gpcr-university #GPCR #DrGPCR #pharmacology #drugdiscovery
- Student Flash Presentations | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
This made me pursue my higher education in the field of adhesion GPCRs. Emmanouil Kyrloglou on the web Adhesion GPCR Consortium LinkedIn A single cell GPCR map of thermogenic , located within the GPCR autoproteolysis inducing (GAIN) domain. graduate student, he worked in the EuGEF Research Group to identify novel prognostic biomarkers and therapeutic Clearly, a new, less toxic therapeutic is needed.
- Eurofins DiscoverX | Dr. GPCR | Dr. GPCR Ecosystem
Your One-Stop-Shop for GPCR Drug Discovery and Development Researchers developing GPCR-targeted therapeutics assay solutions for basic research through therapeutic discovery and development. Principle of Eurofins DiscoverX Cell-based Assays Whether you are developing small-molecule or biologic therapeutic GPCR Podcast Oct 16, 2025 4 min read The Truth About GPCR Product Launches: Years in the Making What cell-based solutions for basic research, discovery, and therapeutic development.
- Session II | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic GPCR Adhesion GPCR BAI1/ADGRB1 can block IGF1R-mediated growth signalling, increase radiosensitivity understanding the molecular basis for human tumor development and how to use this knowledge to devise new therapeutics Van Meir has developed novel therapeutic approaches for cancer using oncolytic adenoviruses and anti-angiogenic Like many other aGPCRs, ADGRG6 undergoes autoproteolysis at the GPCR-autoproteolysis site (GPS) enclosed
- Dr. GPCR Community Presentation | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program GPCR Community Presentation Breaking Barriers: My Journey from Mexico to the Heart of the Dr. GPCR Ecosystem and beyond About Monserrat Avila Zozaya "My doctoral research was focused on investigating My research focuses on understanding the molecular mechanisms of adhesion GPCRs (aGPCRs) in lymphatic GPCR < Previous Session Next Session >
- GPCR Courses
Measuring and understanding bias helps design drugs that maximize therapeutic benefits while minimizing See- The Importance of Pharmacologic Assays Lecture 2: Drug Disposition in Physiological Tissues as a Therapeutic GPCR Ligands as Drugs Lecture 5: Unique Exploitable GPCR-Ligand Behaviors for Therapeutic Benefit Terry GPCR University? Dr. GPCR University Masterclasses?
- GPCR Retreat Logo Contest | Dr. GPCR Ecosystem
Unleash your creativity with this logo contest for the GPCR Retreat 23. Retreat Logo Contest In anticipation of the next GPCR Retreat, we are delighted to announce the GPCR potential for therapeutic interventions. The organizers, including the GPCR retreat founders Dr. Stephen Ferguson and Dr. Transmembranaires du Québec 22nd GPCR Retreat Sponsored by
- Session I | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program Activation: Direct Communication of Extracellular Region with Transmembrane Domain in a Holo-Adhesion GPCR point mutant knock-in mouse, H381S Frank Kwarcinski Tethered Peptide Activation Mechanism of Adhesion GPCRs Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA; Division of Molecular Therapeutics, New York State
- ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic Drugs” closes March 18th! If you’re working on GPCR drug discovery, you know that finding a promising candidate is just the start. A drug must also: ✅ Be absorbed into the body ✅ Reach the right target ✅ Stay long enough to be effective ✅ Cause no harm 📢 Spots are limited—register by March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery | Dr. GPCR Ecosystem
Home → Flash News → ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Courses ⏳ In case you haven’t heard—registration for “Development of GPCR Ligands as Therapeutic 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharmacology #Biotech #DrugDiscovery Previous Next Recent Articles
- Newsletter for Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Subscribe to the Adhesion GPCR Workshop 2024 newsletter. Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Register AGPCR Newsletter Adhesion GPCR Consortium Newsletter - May 2024 Welcome to the 4th official Adhesion GPCR Consortium newsletter GPCR News Register for the Adhesion GPCR 2024 Learn more about the Adhesion GPCR workshop 2024 Up About the event Learn more about the Adhesion GPCR workshop 2024 and its preliminary program.
- 🎯 Crack the code of GPCR ligand development! In case you haven’t heard, Dr. Terry Kenakin is hosting a 4-week course on GPCR drug development—and registration closes in 3 days! ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles ✅ Early safety assessments & toxicity risks 📌 Limited spots—sign up before March 18th! 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research | Dr. GPCR Ecosystem
⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance ✅ PK-PD modeling & therapeutic profiles 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. ⚠️ What you’ll learn: ✅ Drug absorption, metabolism & clearance✅ PK-PD modeling & therapeutic profiles 👉 Development of GPCR Ligands as Therapeutic Drugs | Dr. GPCR Ecosystem #GPCR #DrGPCR #Pharma #Biotech #Research Previous Next Recent Articles
- Leadership, Impact, and GPCR Signaling with Dr. Michelle Halls | Dr. GPCR Ecosystem
Michelle Halls reveals how organized GPCR signaling drives assay innovation and new therapeutic insights concentrations, her work highlights why receptor localization and protein complex assembly matter for therapeutic localized signaling events, how these mechanisms are hijacked in disease, and how they can be leveraged for therapeutic GPCR Premium . GPCR Podcast? Leave a Review.
- Full Agenda for Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Home Registration Full Agenda Venue Travel Tips Sponsors Special Issue on Adhesion GPCRs CINVESTAV, Mexico City, Mexico October 23-25 Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October Read More 12:00 PM Coffee Break with lights snacks Read More 12:30 PM State of the Art Talk Adhesion GPCR GPCR Community Presentation Monserrat Avila Zozaya Read More 11:30 AM Session VIII Physiological and map of thermogenic fat Gavin Zhang NovoiSMART - A new platform for GPCR antibody drug discovery
- From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation | Dr. GPCR Ecosystem
Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics , a company using machine learning to unlock new GPCR-targeted therapies. research career The inside story behind founding Blue Therapeutics and targeting supraspinal pain pathway Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics led Ajay Yekkirala to reshape the future of GPCR-targeted medicine. Enjoying the Dr. GPCR Podcast?
- GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin | Dr. GPCR Ecosystem
From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics GPCR ecosystem , GPCR scientist network , GPCR drug discovery , GPCR training program , GPCR online course , G protein-coupled receptors , GPCR podcast , GPCR webinar series , GPCR data platform Summary created as therapeutic targets. He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general
- 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! Get exclusive access to expert lectures, recordings, reading materials, and even a private call with Dr. Kenakin himself! Don’t miss this chance to level up your knowledge. 🔹 Spots are limited—save yours now! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs #gpcr #drgpcr #pharmacolgy #drugdiscovery #research | Dr. GPCR Ecosystem
Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs GPCR Courses 🚀 Ready to dive into the world of GPCR drug development? Join Dr. Terry Kenakin for the 4-week course “Development of GPCR Ligands as Therapeutic Drugs”! 👉 https://www.ecosystem.drgpcr.com/event-details-registration/development-of-gpcr-ligands-as-therapeutic-drugs
- Session VI | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
particular, drives tumor growth via effects on GBM stem cell self-renewal and metabolism, but also has a therapeutically their therapeutic targeting." Javitch1,2 1Departments of Psychiatry and Molecular Pharmacology and Therapeutics, Columbia University , New York, NY 10032; 2Division of Molecular Therapeutics, New York State Psychiatric Institute, New GPCR < Previous Session Next Session >
- Dr. Christel Menet | Dr. GPCR Ecosystem
I then started my career at Evotec before moving to Domain Therapeutics (called Faust pharmaceutical chemistry. 6 years ago I decided to take on a new challenge by taking the position of CSO at Confo Therapeutics was the 6th employee and today we are more than 60 :) I have fun every day, and I love working with GPCRs Christel Menet on the web Hyphen Projects GPCRS Drug Discovery Confo Therapeutics LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review.
- Dr. Nicolas Gilles | Dr. GPCR Ecosystem
He is pioneering the investigation of animal toxins acting on GPCRs, the largest therapeutic target class His strongest expertise lies in therapeutic target identification and all the steps from venom manipulations pharmacological properties of these new ligands are deemed exceptional, a lead optimization is realized and its therapeutic GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks
- Signals, pH, and Discovery : Cracking GPCR Mysteries with Dr. Ian Chronis | Dr. GPCR Ecosystem
Discover how GPR65 reshapes our understanding of GPCR signaling and its role in cancer, with Dr. GPCR podcast. << Back to podcast list Strategic Partner(s) Signals, pH, and Discovery : Cracking GPCR Yamina underscores the therapeutic potential of GPR65, especially in the context of cancer immunotherapy , and how understanding receptor activity in acidic microenvironments could unlock new therapeutic strategies GPCR Podcast? Leave a Review.
- Dr. Samuel Hoare | Dr. GPCR Ecosystem
company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics , particularly GPCR antagonists. of GPCR function to better target receptors. GPCR Member ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review.
- GPCR Retreat | Dr. GPCR Ecosystem
Discover the essence of GPCR Retreat, an international GPCR Event that empowers the GPCR field. Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat The GPCR Retreat focuses on advances in our understanding of how GPCRs operate in cell communication. Registration to the GPCR Retreat is capped at 200 participants to promote an intimate environment. in the Ottawa 2017 edition, to showcase the breadth of diversity in GPCR trainee communities.
- Dr. GPCR Summit 2022 Live Talks Schedule
drug discovery enabled by the Confo Therapeutics technology Dr. 2022 15:00:00 GMT+0000 (Coordinated Universal Time) Details Enabling the discovery of next generation therapeutics GPCR Ecosystem Partners Tags Dr. GPCR Summit Dr. GPCR Summit 2022 Dr. GPCR Summit 2022 Schedule Dr. GPCR Summit Details Dr. GPCR Summit Pre-Recorded Talks Dr. GPCR Summit Live Talks Dr. GPCR Summit 2022 Submit Poster Presentation for Dr. GPCR Summit 2022
- Class B GPCR drugs are reshaping treatment for migraine, diabetes, and obesity- but did you know ligand bias plays a key role in their success? This new review explores how tweaking peptide drugs can boost efficacy, reduce side effects, and unlock next-gen therapies. Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com/reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr | Dr. GPCR Ecosystem
GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️https://www.ecosystem.drgpcr.com /reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics #gpcr#drgpcr Published on June 2, 2025 Category GPCR Weekly News Class B GPCR drugs are reshaping treatment GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox ➡️ https://www.ecosystem.drgpcr.com /reviews/where-are-we-now%3F-biased-signalling-of-class-b-g-protein-coupled-receptor-targeted-therapeutics
- Dr. Graeme Milligan | Dr. GPCR Ecosystem
main research group centers on the function, structure, and regulation of G protein-coupled receptors (GPCRs Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Imaging in Native Tissue How Collaboration Sparked a GPCR Imaging Breakthrough in Chemical Biology Thanks











